Polyethylene glycol (PEG)-lipids are widely used to engineer the interfacial properties of lipid-based nanomaterials, where they play a central role in governing colloidal stability and biological interactions. Among these PEG Lipids, DSPE-PEG2000 is most commonly used in liposomes, selected lipid nanoparticle (LNP) formulations, polymeric micelles, and other drug delivery systems.

DSPE-PEG2000 combines a hydrophobic phospholipid anchor (DSPE) with a hydrophilic PEG chain. This amphiphilic structure allows the lipid portion to associate with lipid assemblies while the PEG chain extends into the surrounding aqueous phase. Depending on the formulation, this surface modification can affect particle aggregation, protein adsorption, cellular uptake, and in vivo distribution.

Understanding the molecular structure of DSPE-PEG2000, the role of PEG molecular weight, and the available terminal functional groups is important when selecting PEG lipids for drug delivery research.
 

What Is DSPE-PEG2000?

DSPE-PEG2000 is a synthetic PEGylated phospholipid composed of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) linked to a PEG (PEG2000) chain with a molecular weight of approximately 2000 Da.

The DSPE lipid anchor contains two saturated C18 fatty acyl chains and a phosphoethanolamine headgroup. The hydrophobic chains associate with lipid bilayers and other hydrophobic assemblies, while the PEG chain provides a hydrophilic polymer segment that can form a hydrated layer at the particle surface. This combination of hydrophobic anchoring and hydrophilic surface modification makes DSPE-PEG2000 useful in liposomes, selected lipid nanoparticle (LNP) formulations, polymeric micelles, and other nanocarrier systems.

| What Does "2000" Mean in DSPE-PEG2000?

The number "2000" refers to the average molecular weight of the PEG segment, expressed in daltons (Da). It does not represent the total molecular weight of the complete DSPE-PEG molecule or the diameter of the resulting nanoparticle.

PEG molecular weight can influence hydration, chain conformation, steric shielding, and interactions with biological components. Its effects on particle size, colloidal stability, and delivery performance also depend on PEG-lipid content, lipid composition, and the properties of the carrier.

Generally, short PEGs (PEG1000 or shorter) do not prevent protein corona formation and fail to increase the particles' blood circulation time, whereas long PEGs (PEG5000 or longer) can strongly interfere with the cellular uptake or the endosomal escape process. The intermediate length (PEG2000) is commonly used as this provides a good compromise between increased elimination half-time and efficient gene delivery.

| DSPE, DSPE-PEG, and DSPE-PEG2000: What Is the Difference?

DSPE, DSPE-PEG, and DSPE-PEG2000 refer to related but distinct materials.

• ● DSPE is a saturated, zwitterionic phospholipid featuring two hydrophobic stearoyl (C18:0) fatty acid chains and a hydrophilic phosphoethanolamine headgroup.
• ● DSPE-PEG refers to a phospholipid-polymer conjugate composed of DSPE, a PEG chain and a reactive terminal functional group.
• ● DSPE-PEG2000 specifies a PEG segment with a nominal average molecular weight of approximately 2,000 Da.

The PEG terminal group is an important selection parameter. DSPE-mPEG2000 typically refers to a methoxy-terminated PEG lipid used for basic surface PEGylation. Functionalized derivatives, such as DSPE-PEG2000-NH2, DSPE-PEG2000-COOH, DSPE-PEG2000-MAL and DSPE-PEG2000-Mannose provide additional reactive groups for conjugation.
 

Applications of DSPE-PEG2000 in Nanomedicine

| DSPE-PEG2000 Used in Liposomes

Liposomes are spherical or multilayered spherical vesicles made by the self-assembly of diacyl-chain phospholipids (lipid bilayer) in aqueous solutions. PEG is commonly incorporated into liposomal formulations to modify surface properties, reduce interactions with biological components, and potentially extend circulation time in vivo. Among PEGylated lipids, DSPE-PEG2000 is widely used in the development of long-circulating liposomes.

DSPE-PEG2000 consists of a hydrophobic DSPE anchor that associates with the phospholipid bilayer and a hydrophilic PEG2000 chain that can form a protective hydration barrier on the liposome surface. This barrier reduces the adsorption of certain plasma proteins and recognition by the mononuclear phagocyte system (MPS). Under suitable conditions, these effects may prolong blood circulation and influence liposome biodistribution. In some tumor models, prolonged circulation can contribute to increased tumor accumulation through the enhanced permeability and retention (EPR) effect, although the extent of accumulation varies with the formulation and tumor environment.

Doxil® was the first successful PEGylated liposomal formulation. PEGylated stealth liposomes can circulate longer than some conventional liposomal formulations, potentially improving drug exposure at target tissues. 

| DSPE-PEG2000 Used in Lipid Nanoparticles (LNPs)

Lipid nanoparticles (LNPs) typically contain four major components: ionizable lipids, helper lipids, sterols, and PEG-lipids. PEG lipids are widely used to provide the nanoparticles with a unique outer layer. The “stealth” properties of PEG chains can prevent nanoparticle aggregation, reduce nonspecific protein adsorption, and delay immune recognition, thereby extending LNP circulation half-life in the bloodstream.

Shorter-chain PEG-lipids, such as DMG-PEG2000  (C14, dimyristoyl-glycerol), can detach from LNPs relatively rapidly in serum. This property is relevant to the design of liver-directed formulations, including the lipid components used in Onpattro®, an FDA-approved siRNA therapeutic. Short-chain PEG-lipids are also used in COVID-19 vaccines: ALC-0159 (DTA-PEG2000), a C14-based PEG-lipid, is a component of Comirnaty®, while DMG-PEG2000 is used in Spikevax®.

By comparison, PEG-lipids with longer hydrophobic anchors, such as the C18-based DSPE-PEG2000, can associate more strongly with lipid membranes. In selected LNP formulations, DSPE-PEG2000 may help maintain surface PEG coverage, reduce interactions with certain blood components, and potentially extend circulation time. Its effects on biodistribution and tumor accumulation, however, depend on the overall formulation and biological context.

| DSPE-PEG2000 Micelles for Hydrophobic Drug Delivery

DSPE-PEG2000 can be used to prepare nanoscale micelles for the formulation of hydrophobic drugs. In an aqueous environment, its amphiphilic structure can promote self-assembly, with the hydrophobic DSPE portion associating within the micellar core and the hydrophilic PEG2000 chains extending into the surrounding water. This arrangement can help incorporate hydrophobic compounds into an aqueous dispersion and improve their apparent solubility.

DSPE-PEG2000 micelles have attracted interest in drug delivery because of their small size and the potential for relatively low critical micelle concentrations (CMCs). A low CMC can help micelles maintain their assembly upon dilution, although their stability in blood also depends on factors such as formulation composition, drug loading, and interactions with biological components. The PEG layer can provide steric stabilization and reduce some interactions with plasma proteins and cells of the mononuclear phagocyte system (MPS), potentially influencing circulation time and biodistribution.

These characteristics make DSPE-PEG2000-based micelles useful candidates for delivering hydrophobic compounds, including certain anticancer agents. By improving drug dispersion in aqueous media and potentially modifying its distribution in the body, micellar formulations may offer advantages over administering the free drug. However, improvements in circulation time, tumor accumulation, therapeutic efficacy, or safety are not guaranteed and must be evaluated for each drug and formulation. Tumor accumulation through the enhanced permeability and retention (EPR) effect can occur in some settings, but varies with tumor type and other biological factors.
 

Functionalized DSPE-PEG2000 Derivatives for Conjugation and Targeting

In addition to methoxy-terminated DSPE (DSPE-mPEG2000), functionalized DSPE-PEG derivatives provide chemical handles for attaching targeting ligands, fluorescent labels, and other molecules. The appropriate derivative depends on the reactive groups available on the coupling partner and the desired conjugation chemistry.

| DSPE-PEG2000-Amine (DSPE-PEG-NH2)

DSPE-PEG-Amine (MW 2,000) combines a hydrophobic DSPE anchor with a hydrophilic PEG chain terminating in an amino group. The amino group enables covalent conjugation with NHS esters, activated carboxyl groups, and other compatible functional groups, making it useful for attaching fluorescent dyes, targeting ligands, and other molecules to lipid-based nanocarriers.

| DSPE-PEG2000-Mannose

DSPE-PEG-Mannose is a functionalized PEG lipid composed of a hydrophobic DSPE anchor, a hydrophilic PEG spacer, and a terminal mannose group. It can integrate into lipid membranes while providing surface stability and mannose-mediated recognition of specific cell receptors. It is used in targeted drug delivery, vaccine development, and biomaterial research, particularly for applications involving mannose-receptor-expressing cells such as macrophages and certain dendritic cells.

| DSPE-PEG2000-Maleimide (DSPE-PEG-Mal)

DSPE-PEG2000-Maleimide contains a thiol-reactive maleimide group that reacts with free sulfhydryl groups (-SH) in antibodies, peptides, proteins, and other biomolecules to form stable thioether bonds, enabling ligand conjugation for targeted drug delivery and nanoparticle surface functionalization.

| DSPE-PEG2000-NHS

DSPE-PEG2000-NHS is a functionalized PEG lipid used to prepare PEGylated liposomes and micelles. Its NHS ester reacts with primary amines in proteins, antibodies, peptides, and other molecules to form stable amide bonds, enabling biomolecule conjugation and nanoparticle surface functionalization.

| DSPE-PEG2000-Azide (DSPE-PEG-N3)

DSPE-PEG2000-Azide (DSPE-PEG-N3) is an azide-functionalized PEG lipid used for click chemistry conjugation. It reacts with alkyne-containing molecules through copper-catalyzed azide–alkyne cycloaddition (CuAAC) or, with strained alkynes, copper-free click chemistry. These reactions enable the attachment of targeting ligands, imaging probes, and other functional molecules to lipid-based nanoparticles.

| DSPE-PEG2000-Carboxylic Acid (DSPE-PEG-COOH)

DSPE-PEG2000-COOH combines a hydrophobic DSPE anchor, a PEG2000 spacer, and a terminal carboxyl group for further conjugation. The carboxyl group can be activated using EDC/NHS or other coupling reagents to form stable amide bonds with amine-containing molecules, such as targeting ligands and biomolecules, enabling functionalization of nanoparticle surfaces.

| Other Functionalized Derivatives

Other DSPE-PEG derivatives may incorporate biotin, folate or fluorescent labels. These materials can support affinity recognition, exploratory targeting studies, or particle tracking, depending on the ligand and application.

However, attaching a targeting ligand does not automatically confer effective targeting. Ligand accessibility, orientation, surface density, receptor expression, and retention of binding activity can all affect performance. PEG chains may adopt different conformations, and terminal groups or conjugated ligands may interact with the particle surface or neighboring components. Their accessibility should therefore be evaluated experimentally.
 

Conclusion

DSPE-PEG2000 is a versatile PEGylated phospholipid used to modify the surface properties of liposomes, selected LNP formulations, polymeric micelles, and other nanocarrier systems. Its benefits are formulation-dependent. PEGylation may help reduce aggregation and prolong circulation in some systems, but excessive surface shielding can also limit cellular interactions and intracellular delivery.

Functionalized derivatives, including DSPE-PEG2000-NH2, DSPE-PEG2000-Mannose, DSPE-PEG2000-COOH, DSPE-PEG2000-MAL, and DSPE-PEG2000-NHS, provide additional options for conjugation and surface modification.

For researchers developing lipid-based drug delivery systems, the appropriate DSPE-PEG2000 derivative should be selected according to the required surface properties, conjugation chemistry, and intended application. Its performance should then be confirmed through physicochemical characterization and application-specific testing.
 

Biopharma PEG - DSPE PEG Supplier

Biopharma PEG provides a comprehensive portfolio of DSPE-PEG lipids, functional DSPE-PEG derivatives with diverse end groups and molecular weights, and custom PEG-lipid synthesis for drug delivery research. We support tailored solutions based on specific formulation, conjugation, and characterization requirements.

Quality is central to our commitment. Our manufacturing processes are supported by a robust Quality Management System (QMS), with GMP-grade options available for applicable products. We use advanced, orthogonal analytical techniques to assess purity and support lot-to-lot consistency, including 400 MHz NMR, HPLC, MALDI-TOF MS, GC, LC, GC-MS, and LC-MS.

​From research-scale materials to customized synthesis, Biopharma PEG supports your development with reliable PEG-lipid solutions and analytical expertise. Contact us at [email protected] to discuss more details. 

References:
[1]Cisneros EP, Wijesekera AS, Volpatti LR. Chemical and Biological Determinants of PEG-Lipid Shedding From Therapeutic Nanoparticles. Small. 2026 Sep 10:e75613. doi: 10.1002/smll.75613. Epub ahead of print. PMID: 42723396.
[2]Nsairat H, Khater D, Sayed U, Odeh F, Al Bawab A, Alshaer W. Liposomes: structure, composition, types, and clinical applications. Heliyon. 2022 May 13;8(5):e09394. doi: 10.1016/j.heliyon.2022.e09394. PMID: 35600452; PMCID: PMC9118483.
[3]Takayama, R.; Inoue, Y.; Murata, I.; Kanamoto, I. Characterization of Nanoparticles Using DSPE-PEG2000 and Soluplus. Colloids Interfaces 2020, 4, 28. https://doi.org/10.3390/colloids4030028
[4]Berger M, Degey M, Leblond Chain J, Maquoi E, Evrard B, Lechanteur A, Piel G. Effect of PEG Anchor and Serum on Lipid Nanoparticles: Development of a Nanoparticles Tracking Method. Pharmaceutics. 2023 Feb 10;15(2):597. doi: 10.3390/pharmaceutics15020597. PMID: 36839919; PMCID: PMC9962341. 

Related Technical Articles & Guides

• ● Lipid Nanoparticles (LNPs) in mRNA Drug Delivery: Mechanisms, and Future Applications
• ●PEG Lipids: Definition, Structure & Key Applications 
• ● The Role of Four Lipid Components Of LNPs
• ● Ultimate Insight into PEG Derivatives and Its Application